| KemPharm is a specialty pharmaceutical company focused on the discovery and development of prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT), technology. Co.'s product candidate pipeline is focused on the areas of attention deficit hyperactivity disorder (ADHD), and stimulant use disorder (SUD). Co.'s clinical development candidates, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but with differing extended-release, effect profiles, and are intended for the treatment of ADHD. KP879, a prodrug of d-methylphenidate using Co.'s LAT technology, is Co.'s product candidate for the treatment of SUD. The KMPH YTD return is shown above.
The YTD Return on the KMPH YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether KMPH YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the KMPH YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.